Appendix A – domain data

At 3 months	% (n) no problems					Utility weight	VAS
	Mobility	Pain	Anxiety	ADLs	Selfcare		
All	58.5% (131)	40.6% (91)	54.9% (119)	58.5% (131)	81.7% (183)	0.77	75
Sex							
Male	61.3% (57)	47.3% (44)	63.4% (59)	63.4% (59)	86.0% (80)	0.84	80
Female	38.9% (70)	20.8% (43)	31.6% (60)	37.4% (68)	74.2% (98)	0.74	75
Age							
<40	89.5% (17)	57.9% (11)	52.6% (10)	78.9% (15)	94.7% (18)	0.88	80
40-49	53.7% (22)	41.5% (17)	29.3% (12)	43.9% (18)	70.7% (29)	0.66	66
50-59	66.7% (40)	43.3% (26)	50.0% (30)	66.7% (40)	80.0% (48)	0.77	80
60-69	52.1% (38)	31.5% (23)	64.4% (47)	56.2% (41)	83.6% (61)	0.77	75
70+	43.5% (10)	47.8% (11)	78.3% (18)	56.5% (13)	87.0% (20)	0.79	80
Referral reason							
Alcohol excess	58.1% (25)	41.9% (18)	46.5% (20)	60.5% (26)	74.4% (32)	0.79	80
NALFD	56.3% (45)	40.0% (32)	55.0% (44)	56.3% (45)	86.3% (69)	0.77	68
Abnormal liver enzymes	60.7% (51)	39.3% (33)	59.5% (50)	57.1% (48)	79.8% (67)	0.77	75
Liver fibrosis category							
No significant liver disease	64.4% (105)	42.9% (70)	57.1% (93)	63.8% (104)	84.7% (138)	0.79	80
Significant liver disease	45.2% (19)	35.7% (15)	42.9% (18)	47.6% (20)	76.2% (32)	0.70	70
Advanced liver disease	30.8% (4)	23.1% (3)	61.5% (8)	30.8% (4)	69.2% (9)	0.65	66

At 12 months	% (n) no problems					Utility weight	VAS
	Mobility	Pain	Anxiety	ADLs	Selfcare		
All	67.6% (161)	48.3% (115)	61.8% (147)	68.9% (164)	84.5% (201)	0.81	80
Sex							
Male	71.7% (81)	53.1% (60)	66.4% (75)	69.9% (79)	82.3% (93)	0.85	80
Female	45.3% (78)	27.6% (54)	38.9% (70)	49.7% (83)	73.6% (106)	0.77	80
Age							
<40	80.8% (21)	57.7% (15)	46.2% (12)	76.9% (20)	80.8% (21)	0.88	80
40-49	80.6% (29)	63.9% (23)	55.6% (20)	63.9% (23)	83.3% (30)	0.82	75
50-59	67.7% (42)	45.2% (28)	53.2% (33)	67.7% (42)	80.6% (50)	0.80	80
60-69	53.9% (41)	38.2% (29)	63.2% (48)	60.5% (46)	80.3% (61)	0.75	80
70+	70.6% (24)	55.9% (19)	82.4% (28)	82.4% (28)	97.1% (33)	0.86	80
Referral reason							
Alcohol excess	62.5% (30)	47.9% (23)	56.3% (27)	64.6% (31)	81.3% (39)	0.77	80
NALFD	60.2% (50)	39.8% (33)	55.4% (46)	61.4% (51)	79.5% (66)	0.77	73
Abnormal liver enzymes	76.8% (73)	55.8% (53)	70.5% (67)	75.8% (72)	89.5% (85)	0.85	80
Liver fibrosis category							
No significant liver disease	71.3% (124)	50.6% (88)	60.9% (106)	71.8% (125)	86.8% (151)	0.84	80
Significant liver disease	64.7% (33)	47.1% (24)	62.7% (32)	64.7% (33)	80.4% (41)	0.80	80
Advanced liver disease	30.8% (4)	23.1% (3)	69.2% (9)	46.2% (6)	69.2% (9)	0.69	75

Appendix B – sensitivity analysis

HRQoL scores								
		% no problems					Utility weight	VAS
		Mobility	Pain	Anxiety	ADLs	Self-care		
Pre-diagnosis	No significant liver disease	57.0% (61)	27.1% (29)	48.6% (52)	59.8% (64)	85.0% (91)	0.75	80
	Significant liver disease	41.9% (13)	19.4% (6)	61.3% (19)	51.6% (16)	77.4% (24)	0.69	80
	Advanced liver disease	20.0% (2)	20.0% (2)	60.0% (6)	30.0% (3)	70.0% (7)	0.66	73
3-months	No significant liver disease	65.4% (70)	44.9% (48)	57.9% (62)	65.4% (70)	86.9% (93)	0.80	80
	Significant liver disease	48.4% (15)	35.5% (11)	54.8% (17)	54.8% (17)	80.6% (25)	0.77	70
	Advanced liver disease	40.0% (4)	30.0% (3)	60.0% (6)	40.0% (4)	80.0% (8)	0.69	68
12-months	No significant liver disease	71.0% (76)	52.3% (56)	62.6% (67)	72.0% (77)	88.8% (95)	0.84	80
	Significant liver disease	71.0% (22)	41.9% (13)	61.3% (19)	67.7% (21)	83.9% (26)	0.80	80
	Advanced liver disease	30.0% (3)	30.0% (3)	70.0% (7)	50.0% (5)	70.0% (7)	0.70	78

Change in utility index					
		Pre-diagnosis to 3 months		Pre-diagnosis to 12 months	
All	n=148	+0.02 (0.21)	p=0.122	+0.06 (0.20)	p<0.001
No significant liver disease	n=107	+0.02 (0.22)	p=0.150	+0.07 (0.20)	p<0.001
Significant liver disease	n=31	+0.02 (0.19)	p=0.471	+0.05 (0.23)	p=0.089
Advanced liver disease	n=10	-0.01 (0.23)	p=0.813	+0.01 (0.23)	p=0.944

ADLs activities of daily living; **VAS** visual analogue scale
Values are % (n) or mean (sd)

Appendix C - STROBE Statement (cohort studies)

	Item No	Recommendation	
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	✓abstract
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	✓
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	✓
Objectives	3	State specific objectives, including any prespecified hypotheses	✓
Methods			
Study design	4	Present key elements of study design early in the paper	✓
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	✓
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	✓
		(*b*) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	✓
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement).	✓

		Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	✓
Study size	10	Explain how the study size was arrived at	✓
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	✓
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	✓
		(*b*) Describe any methods used to examine subgroups and interactions	✓
		(*c*) Explain how missing data were addressed	✓
		(*d*) If applicable, explain how loss to follow-up was addressed	✓
		(*e*) Describe any sensitivity analyses	✓
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	✓ fig1
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	✓ fig1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	✓ tab1

		(b) Indicate number of participants with missing data for each variable of interest	✓ tab1
		(c) Summarise follow-up time (eg, average and total amount)	✓ p6
Outcome data	15*	Report numbers of outcome events or summary measures over time	✓ tab2-3
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	✓ CI
		(*b*) Report category boundaries when continuous variables were categorized	✓
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	✓ App
Discussion			
Key results	18	Summarise key results with reference to study objectives	✓
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	✓
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of	✓

		analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	✓
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	✓

*Give information separately for exposed and unexposed groups.